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HIV strain characterization and phyloge-
netic analysis have played a key role in
elucidating epidemiologic and historical aspects
of HIV transmission worldwide (1). In Thailand,
for example, molecular analyses of virus isolates
documented the independent introduction and
spread of two different HIV-1 subtypes, B and E,
as well as the increasing proportion of subtype E
relative to B in injection drug users over time (2-
8). Information from these studies clarified the
dynamics of the Thai epidemic and influenced the
decision to introduce a bivalent subtype B/E
vaccine in the first HIV-1 vaccine efficacy trials
recently initiated there (6). However, few other
studies have described HIV-1 strains or the
phylogenetic relationships of sequences from
infections sampled in a systematic manner. This
is especially true in central Africa, where the HIV
epidemic has been present for a relatively long
time (1-3,6,7,9-12).
Uganda, where the prevalence of HIV-1 is
one of the highest in the world, has been a focus of
research and intervention efforts, including
vaccine development for the first vaccine trial in
Africa. Previous studies documented HIV-1
subtypes A and D as important strains, with a
limited distribution of other variants (13-19). The
primary objective of our study was to character-
ize the recent virus isolates of the HIV-1 epidemic
in Uganda by describing the distribution and
genetic diversity of the principal HIV-1 subtypes.
Methods
In an ongoing collaborative effort between
the Uganda Virus Research Institute and the
Centers for Disease Control and Prevention to
study HIV-1 genetic diversity, isolates from a
number of different clinical sites and counseling
and testing centers in Uganda were collected and
characterized (19). To obtain uniform and
consistent sampling over time from the Kampala
and Mpigi districts of central Uganda, where
most specimens were collected, we selected two
sites in Kampala (Mulago Hospital, Nsambya
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To better characterize the virus isolates associated with the HIV-1 epidemic in
Uganda, 100 specimens from HIV-1-infected persons were randomly selected from
each of two periods from late 1994 to late 1997. The 200 specimens were classified into
HIV-1 subtypes by sequence-based phylogenetic analysis of the envelope (env) gp41
region; 98 (49%) were classified as env subtype A, 96 (48%) as D, 5 (2.5%) as C, and
1 was not classified as a known env subtype. Demographic characteristics of persons
infected with the two principal HIV-1 subtypes, A and D, were very similar, and the
proportion of either subtype did not differ significantly between early and later periods.
Our systematic characterization of the HIV-1 epidemic in Uganda over an almost 3-year
period documented that the distribution and degree of genetic diversity of the HIV
subtypes A and D are very similar and did not change appreciably over that time.610
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Table 1. Demographic characteristics of persons infected
with HIV-1 subtype A or D
  Sub-   Sub-
 type A  type D
Characteristics n=98 n=96
Period






Mean 31.2 30.8 p=0.39
Sex
Female 66% 73% p=0.26
Male 34% 27%
Marital status





UVRIa (Mpigi) 37% 33% p=0.81
Mulago (Kampala) 23% 24%
Nsambya (Kampala) 40% 43%
aUVRI = Uganda Virus Research Institute.
Mobile Unit) and one site in Entebbe (Uganda
Virus Research Institute Clinic). From more than
1,800 specimens collected from these sites from
late 1994 through 1997, we chose all seropositive
specimens from the earliest period (the last
quarter of 1994 through the first quarter of 1995,
n=393, and the last two quarters of 1997, n=135).
After determining that the major demographic
factors, such as mean age (p=0.76), age group
(p=0.20), sex (p=0.12), and marital status
(p=0.14), were not significantly different between
persons seen in either period, we selected 100
specimens at random from each period for further
analysis. Because local resources were limited,
clinical (World Health Organization stage) and
immunologic (CD4 and CD8 counts) data were
available from only a subset of patients. Although
limited by the number of specimens available and
by laboratory capacity, our sample size could
detect a minimum absolute change of more than
20% in either subtype A or D with a power of 80%
and with 95% confidence.
Data collection, specimen processing, viral
isolation, and polymerase chain reaction (PCR)
amplification of the env gp41 fragment (460 bp)
used methods previously described (19-21). After
amplification, DNA from the nested PCR was
cycle-sequenced (60 ng DNA per sequencing
reaction) with the ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction Kit (Perkin-
Elmer, Foster City, CA), according to
manufacturer’s protocol, by using the PCR
nested primers gp46F2 and gp47R2 (21).
Results
Of all 200 specimens, 98 (49%) were classified
as env subtype A, 96 (48%) as D, 5 (2.5%) as C, and
1 unclassified into a known env subtype category.
The demographic characteristics of persons
infected with the two principal HIV-1 subtypes, A
and D, were very similar, and the proportion of
either subtype did not differ significantly between
early and later periods (Table 1). In addition,
there were three subtype C isolates and one
isolate of undetermined subtype in the early period
and two subtype C isolates in the later period.
The Figure  illustrates the phylogenetic trees
for all HIV-1 env subtype A and D isolates. The
mean pairwise intrasubtype nucleotide diver-
gence for env  gp41 was 7.8% (3.6%-22.3%) for
subtype A specimens and 7.2% (2.8%-12.5%) for
subtype D specimens. The translated amino acid
regions of gp41 revealed only minor substitutions
in subtypes A and D (data not shown). When
specimens were further stratified by period and
clinic, intrasubtype divergence of the two
subtypes was similar, with the percentage of
divergence slightly higher in the later period
(Table 2). There was no clear segregation or
clustering by period or locale (Figure).
In the subset of persons with clinical or
immunologic data, the clinical characteristics of
persons infected with env subtype A or D were
very similar; any differences were not significant
(Table 3).
Discussion
Our detailed and systematic characterization
of the HIV-1 epidemic in Uganda over an almost
3-year period has shown that the distribution and
degree of genetic diversity of the two predomi-
nant env subtypes, A and D, are very similar and
have not changed appreciably over that time.
However, there are two caveats when interpret-
ing our results. First, our sample was collected
cross-sectionally without known dates of infec-
tion. Second, our available sample size was not
large enough to document small changes in the
proportion of either A or D subtypes. Neverthe-
less, the proportion of those two subtypes
observed in specimens from the two periods were
virtually identical.611
Research
Vol. 6, No. 6, November–December 2000 Emerging Infectious Diseases
Our results are consistent with those of
previous studies indicating that both subtypes A
and D have been present as major strains in the
Ugandan epidemic since the mid-1980s (13-17).
The similar mean and range of intrasubtype
variation for subtypes A and D in the env gp41
region in this report, as well as in the env C2-V3
we reported earlier (19), also suggest that the two
predominant HIV-1 subtypes have both been
present in Uganda for a relatively long period.
The lack of significant clustering by period or
clinic in the phylogenetic analyses suggests that
infections from both subtypes are transmitted in
a broad, heterogeneous manner in central
Uganda. Similarly, our examination of a subset of
patients with clinical or immunologic data, in
combination with similar overall demographic
characteristics, suggests that persons with
subtype A or D had similar levels of immune
suppression. Since this information was indepen-
dently collected at three sites before genetic
characterization of infecting HIV-1 strains, a
systematic selection bias with respect to subtype
appears unlikely.
Although we did not document any major
recent changes in the proportion of subtypes A or
D, our ongoing surveys may show future changes
in subtype distribution. In contrast to the large
proportion of subtypes A and D, the proportion of
subtype C appeared to be small in both periods
studied and in our earlier study (19). The minor,
nonexpanding, role of subtype C in central
Uganda contrasts with the higher proportions of
C in southeastern Africa. Recently, we reported
that subtype C isolates from Uganda formed a
distinct subcluster, unlike subtype C isolates
from other locales (24).
The presence or absence of significant
changes in subtype distribution in different
populations is ecologic and by itself does not
constitute definitive evidence for or against
potential subtype-specific differences in trans-
missibility, pathogenesis, or clinical symptoms
(25). In Uganda, where subtypes A and D are
found in a large proportion of the population,
current and future prospective studies will help
to address these crucial research questions.
Although few countries, especially those with
limited resources, have the necessary infrastruc-
ture to systematically monitor the HIV-1
epidemic, periodic molecular analyses such as
this one in Uganda are needed, particularly if
trials of subtype-specific vaccines are being
considered. Since the HIV-1 pandemic is
becoming increasingly complex, with greater
heterogeneity and the presence of recombinant
viruses (26), a major challenge will be to develop
cost-effective technologies to characterize viruses
without sequencing (1). While more rapid typing
methods are available to determine the subtype
distribution (19), we needed the labor-intensive
sequencing and phylogenetic analysis in this
study to describe the genetic diversity in detail.
Table 2. Mean (range) percentage of pairwise nucleotide divergence stratified by time period, subtype, and clinic (district)
% Mean (range)
Subtype by clinic (district) 1994-95 1997 Overall
Subtype Aa
UVRIb (Mpigi) 5.0 (3.6- 9.5) 7.7 (3.9-12.6) 6.4 (3.6-12.6)
Mulago (Kampala) 7.3 (3.9-10.4) 8.3 (4.2-14.0) 7.8 (3.9-14.0)
Nsambya (Kampala) 7.3 (3.9-11.7) 10.8(3.9-22.3) 9.1 (3.9-22.3)
Subtype D
UVRI (Mpigi) 5.9 (3.1- 8.8) 8.0 (2.8-12.4) 6.9 (2.8-12.4)
Mulago (Kampala) 7.9 (3.6-12.4) 6.7 (3.1- 9.8%) 7.2 (3.1-12.4)
Nsambya (Kampala) 6.4 (3.3- 9.5) 8.5 (3.9-12.5) 7.4 (3.3-12.5)
aSince two isolates from 1994-1995 were almost identical and may represent persons who were epidemiologically linked, these
were treated as one sequence for overall calculations.
bUVRI = Uganda Virus Research Institute.
Table 3. Clinical characteristics among a subset of
persons infected with HIV-1 subtype A or Da
Characteristic Subtype A Subtype D
WHOa clinical   n=37   n=46 p value
 Stage
1 or 2     8%    9%  p=0.97
3    57%   54%
4 (AIDS)    35%   37%
CD4   n=29   n=26
Mean    253    187  p=0.24
Range  19-1,061   2-713
CD8   n=29   n=26
Mean    812    734  p=0.45
Range 288-2,000 139-1,458
aWHO = World Health Organization.612
Research
Emerging Infectious Diseases Vol. 6, No. 6, November–December 2000
Figure. Phylogenetic classification of env gp41 HIV-1 sequences from Ugandan (UG) patients (GenBank accession numbers for
subtypes A and D are pending). Numbers before the abbreviation UG indicate the year of specimen collection; c1, c7, and c9
denote the UVRI, Mulago, and Nsambya clinics, respectively. The trees were constructed on the basis of 354-bp DNA sequences
by the neighbor-joining method with nucleotide distance datum sets calculated by Kimura’s two-parameter approach and
rerooted by using SIV-cpz as the outgroup. Arrows indicate reference subtype A and D sequences; asterisks indicate sequences,
which decrease the bootstrap value from 90% to 73% in subtype A and from 85% to 55% in subtype D sequences. The scale bar
indicates the evolutionary distance of 0.10 nucleotides per position in the sequence. Vertical distances are for clarity only. An
automated DNA sequencer (Applied Biosystems Model 373, Foster City, CA) was used to generate sequence data for alignment613
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with the CLUSTAL version V multiple sequence alignment program and subsequent phylogenetic analysis. Phylogenetic
relationship of sequences was analyzed by the neighbor-joining method (PHYLIP package version 3.5c with and without
bootstrapping), and the maximum-likelihood method (fastDNA program, version 1.0.8, which uses randomized data input and
global rearrangement). The stability of tree topology was tested by pruning, which consisted of removing one species from the
alignment and rerunning the phylogenetic analysis. Accurate subtype determination using env gp41 has been shown to be
similar to that based on env C2V3 sequences (22). The gp41 DNA sequences Environment package, and immunodominant
regions were analyzed (23). The reference sequences for subtypes A-J, groups O and N, and SIVcpz were retrieved from the 1997
HIV-1 Molecular Immunology Database (Los Alamos National Laboratory, Los Alamos, NM).614
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Furthermore, given the time and resources
necessary to develop vaccine candidates, confir-
mation from this and previous studies that
subtypes A and D continue to be the predominant
subtypes with consistently minor contributions
from other strains may have important implica-
tions for vaccine research.
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